Skip to main content
SupplementScience

Noopept Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Emerging

Noopept was developed at the Russian Academy of Medical Sciences and has been studied primarily in Russian clinical literature. Ostrovskaya et al. (2007) demonstrated its neurotrophic properties, showing increased BDNF and NGF expression. Gudasheva et al. (1997) established its potency at 1000x piracetam by weight. Russian clinical trials have shown cognitive benefits in patients with mild cognitive impairment and post-stroke cognitive deficits. Western clinical trials are limited, and most evidence comes from preclinical models and Russian clinical literature.

Evidence by Condition

ConditionStudied DoseEvidence
Cognitive enhancement10-30mg daily in divided dosesEmerging
Neuroprotection10-20mg dailyEmerging
Memory support20mg dailyEmerging
Full Noopept Guide

References

  1. (). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of Experimental Biology and Medicine. DOI
  2. (). The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. European Journal of Drug Metabolism and Pharmacokinetics. DOI
  3. (). Neuroprotective effect of novel cognitive enhancer noopept on AD-related mechanisms in vitro and in vivo. Experimental Neurology. DOI